Background Preoperative transarterial embolization has been utilized in the surgical treatment of metastatic renal cell carcinoma of the femur to decrease perioperative blood loss. However, few studies have documented its efficacy in decreasing the proportion of patients receiving transfusions in the setting of prophylactic treatment of impending pathologic femur fractures. Questions/purposes In a population of patients with metastatic renal cell carcinoma of the femur who underwent prophylactic fixation, the purpose of this study was to quantify and compare the proportion of patients who received at least one transfused unit of blood between a group treated with preoperative embolization and a group without preoperative embolization. Methods A retrospective study was performed using a Medicare claims-based database. International Classification of Diseases, 9
Classification of Diseases, 9
th Revision and Current Procedural Terminology codes were used to identify 1285 patients with metastatic renal cell carcinoma of the femur who underwent prophylactic fixation. The proportion of patients who received one or more blood transfusions was compared between 135 patients who underwent preoperative embolization and a group of 1150 concurrent control patients who did not undergo preoperative embolization. The control group was older than the embolization group, with 44% of these patients > 75 years old and 33% of the embolization group > 75 years. There was no difference in the female:male ratio between groups. Statistical comparisons of outcomes related to transfusion percentages were performed using Pearson chi square analysis with p < 0.05 considered significant. With the numbers available, we had 80% power to detect a difference in the percentage of patients transfused of 11% between the study groups at a = 0.05. Conclusions Preoperative embolization may not be mandatory in the prophylactic treatment of metastatic renal cell carcinoma of the femur, as demonstrated by the 69% of patients who received zero units of blood despite not receiving embolization. However, assessment of the efficacy of embolization in decreasing blood loss in the current study is limited as a result of biases associated with the database design of the study; the decision of whether to send a patient for embolization should be made on a caseby-case basis. The current study does not identify specific risk factors that should factor into this decision and Each author certifies that neither he, nor any member of his immediate family, has funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request. Clinical Orthopaedics and Related Research® neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDAapproval status, of any drug or device prior to clinical use.
Introduction
Increasing evidence has associated allogenic blood transfusion with an increased risk of infections, longer hospital stays, increased likelihood of discharge to an inpatient facility, and even mortality in some patient populations [5, 8, 9, 13, 18] . Patients with malignant skeletal metastasis may be at high risk of anemia related to the primary disease or chemotherapy use, and consequently may be at higher risk of receiving a blood transfusion. Furthermore, operative treatment of metastatic hypervascular tumors has been associated with high levels of blood loss [1, 3, 6, 10, 12, 15, 16] . Thus, strategies to decrease perioperative blood loss and minimize transfusion of allogenic blood products are of interest to treating physicians of oncologic patients in orthopaedics. Preoperative transarterial embolization of metastatic hypervascular tumors has been proposed as a means to decrease perioperative blood loss and transfusion rates and in the past several decades has been widely accepted and utilized in treatment of metastatic renal cell carcinoma of the skeleton [1, 3, 4, 6, 7, 11, 16, 17, 20, 21, 22] . Given the rarity of this disease and its highly variable presentation and treatment, comparisons between transarterial embolization and control groups are limited to a few studies with relatively small numbers of patients [1, 15, 17, 24] . Embolization may be risky in patients who may also have associated medical comorbidities such as renal disease and there are no firm guidelines regarding which patients will benefit from embolization. We therefore evaluated a large insurance database to identify a cohort of patients with metastatic renal cell carcinoma of the femur who underwent prophylactic fixation to compare utilization of blood transfusion between a group of patients who underwent preoperative embolization and a group of patients who did not undergo embolization.
Patients and Methods
The PearlDiver Medicare Standard Analytical Files Database (PearlDiver Technologies, Inc, West Conshohocken, PA, USA) is an insurance claims-based database of patient records and was used for this study. The database contains over 51 million patient lives from 2005 to 2012. International Classification of Disease, 9th Revision (ICD-9) codes and Current Procedural Terminology (CPT) codes were used to identify patients for study based on codes for specific diagnoses and procedures. Given this was a database study with no personal health history traceable to any patient, no institutional review board approval was required at our institution. The patient population was identified as patients with renal cell carcinoma (ICD-9 189.0) with established bone metastasis (ICD-9 198.5). Patients who underwent prophylactic fixation of the femur (ICD-9 78.55) were identified, and from this population, an intervention group was established based on those who underwent a transarterial embolization procedure (ICD-9 39.77, ICD-9 39.79, ICD-9 38.80, ICD-9 38.88, CPT 37204, CPT 37243) within 1 day of surgery and those who did not undergo such a procedure before surgery. The primary outcome measure was the proportion of patients who received packed red blood cell transfusion within 7 days of the operation (ICD-9 99.04). Information on patient sex and age was collected from the database.
A total of 1285 patients with metastatic disease of the femur treated with prophylactic fixation were identified with 135 of these patients undergoing preoperative embolization ( Fig. 1 ). In the group of patients with metastatic renal cell carcinoma of the femur who underwent prophylactic fixation, patients in the embolization group were more likely to be < 75 years old than the group not undergoing embolization (Table 1 ). There were no differences in the male:female ratio in either group.
Statistical Analysis
Statistical comparisons of categorical baseline characteristics and outcomes were performed using Pearson chi square analysis or Fisher's exact testing when patient groups were less than or equal to five. For all statistical comparisons, p < 0.05 was considered significant. Stata Statistical Software, Release 14 (StataCorp LP, College Station, TX, USA) was used for all statistical testing. With the numbers available, we had 80% power to detect a difference in the proportion of patients transfused of 11% between the study groups at a = 0.05.
Results
In the embolization group, 41 of 135 (30%) patients received at least one transfusion, and in the nonembolization group, 359 of 1150 (31%) patients received a transfusion. No difference in transfusion percentage was observed between the embolization and control groups, 30% and 31%, respectively (relative risk, 0.97; 95% confidence interval, 0.74-1.27; p = 0.84; Fig. 2) . No difference in transfusion percentages was seen in any of the age subgroups ( Table 2 ). The percentage of all patients who received a transfusion was 31% (400 of 1285).
Discussion
In the past two decades, allogenic blood transfusion has been associated with multiple complications, and thus treatment strategies to decrease perioperative blood loss are of interest to orthopaedic surgeons treating patients with hypervascular skeletal metastases [8, 9, 13, 18] . Preoperative transarterial embolization has been utilized in the treatment of osseous metastatic disease for several decades with case reports dating back to the 1970s [3, 4, 7, 14, 20, 23] . Since these initial reports, the procedure has gained widespread acceptance and has been applied preoperatively in an attempt to minimize perioperative blood loss and transfusion use in patients with metastatic disease of the long bones [1, 2, 15, 17] . The current study identified a large cohort of patients with metastatic renal cell carcinoma of the femur who underwent prophylactic fixation and compares utilization of blood transfusion between a group of patients who underwent preoperative embolization and a group of patients who did not undergo embolization. In the study population, 69% of patients received no blood transfusions in the first 7 postoperative days. With the numbers available, there was no difference in transfusion percentages between the study groups, with 31% of the control group receiving one or more units of blood and 30% of the embolization group.
There are several limitations of the current study. Given the nonrandomized nature of the study, selection bias may have been introduced, with patients believed most likely to experience high perioperative blood loss being more likely to be included in the embolization group. This would bias the results such that an ability to detect a major reduction in transfusion rates between intervention and control groups would be diminished. The volume of blood transfused cannot Volume 476, Number 3 Preoperative Embolization and Transfusion 531 be reported as a result of the database design of the study. Specifically, it is possible that the overall volume of blood transfused per patient in the embolization group was lower than in the control group. This is a critically important limitation to the data, and it should be emphasized that the results from the current study would not justify abandonment of preoperative embolization altogether as a strategy to decrease blood loss, especially for patients who are at high risk for perioperative blood loss, perhaps including those with large tumors or low preoperative hemoglobin. Acknowledging this important limitation, the authors believe the key clinical message from the study is that 69% of the patients who had surgery without preoperative embolization received no transfusions at all, suggesting that preoperative embolization may not be mandatory in all patients undergoing prophylactic treatment for renal cell metastases. Unfortunately from this database, we cannot identify the characteristics of the patients who did not receive embolization. This subgroup of the study population emphasizes the need for further research that can delineate which patients are most and least likely to benefit from embolization.
Other clinically important complications and benefits of preoperative embolization such as length and difficulty of surgery cannot be assessed with the current study design. The study cannot identify which patients received radiation or chemotherapy. The current study relies on coding to identify patients, and these codes may have been established by professional coders, not treating physicians. The degree of agreement between coders and treating physicians in this study population has not been reported, and confirmation with chart review is not possible. We could not control for the criteria for using blood transfusions in these patients and it is well known that indications for transfusion have changed over time and likely vary between different physicians and centers. Preexisting medical conditions in addition to surgical blood loss might have influenced the use of transfusion from the surgical procedure or there may have been other reasons for transfusion such as bleeding from other causes. The Medicare database used in this study relies on ICD-9 procedural codes for inpatient procedures, and differentiation between intramedullary nailing and other means of prophylactic fixation is not possible. However, it is assumed that the majority of patients who underwent prophylactic fixation in this study were treated with intramedullary nailing. The database design of the current study limits characterization of patient, tumor, and surgical variables, including preoperative hemoglobin, utilization of curettage intraoperatively, and tumor size, all of which may contribute to transfusion and blood loss in surgical treatment of femur fractures [11, 15, 16, 19] . This implicit limitation further limits the capacity for direct comparisons between the studies.
No difference in the proportion of patients who received transfusions was observed between the embolization group and the control group. Findings from this study are in agreement with those of Pazionis et al. relating to the lack of demonstrated benefit of preoperative transarterial embolization in femoral intramedullary nailing procedures [15] . The extent to which preoperative embolization decreases perioperative blood loss and transfusion remains controversial. Given the widespread acceptance and utilization of transarterial embolization in the treatment of osseous metastatic disease, many studies have not included control groups [1, 20, 21] . There are, however, several studies examining patients with metastatic long bone disease comparing results of transarterial embolization with control groups without transarterial embolization (Table 3 ) [1, 15, 17] . In their 1989 study, Roscoe et al. [17] reported a decrease in estimated blood loss in 10 patients with metastatic renal cell carcinoma of the femur who underwent preoperative transarterial embolization relative to 20 historical control subjects at their institution who did not undergo transarterial embolization. The rate of transfusion and mean volume transfused were not reported. Barton et al. [1] published results from 61 transarterial embolization procedures involving 36 patients with metastatic renal cell carcinoma. In their series, three patients had metastatic disease to the femur. Their overall results demonstrated a reduction in estimated blood loss in the transarterial embolization group compared with 20 historical control subjects from their institution. Neither rate of transfusion nor volume of transfused blood was reported. A recent well-designed, case-control study by Pazionis et al. [15] compared patients who underwent preoperative transarterial embolization with closely matched control subjects. Notably, the population in their study consisted of patients in whom the use of transarterial embolization was controversial with patients most likely and least likely to benefit from the procedure excluded from their analysis. They noted decreased estimated blood loss, volume of blood transfused, and operative time in the subgroup analysis of 14 patients with femoral disease undergoing open procedures. In the subgroup analysis of 16 patients with femoral disease who underwent femoral nailing, no reduction in transfusion volume was demonstrated [15] . The clinical utility of the current study is that it demonstrates that preoperative embolization may not be mandatory in the prophylactic treatment of metastatic renal cell carcinoma of the femur. This is demonstrated by the 69% of 1150 patients treated with prophylactic femur fixation who did not receive embolization and received no blood transfusions at all. These data suggest that the determination of whether a patient with renal cell metastases to bone should undergo preoperative embolization should be made on a case-by-case basis. The current study does not identify specific risk factors that should factor into this decision and underscores the need for further research in this regard. A plausible future research design to account for the selection bias and other data limitations that plague the current study as well as the existing literature would be a multicenter retrospective case-control study, which would allow a larger volume of patients than the existing literature and increased patient-specific detail than the current study. Such a study should include pathologic fractures in addition to femurs treated prophylactically. Important variables including tumor size, preoperative hemoglobin and platelet levels, medical comorbidities, and surgical treatment variables could be included in the data set and corrected for in the analysis. Such a study could identify and quantify risk factors that would help to target which patients may benefit most from embolization. Ideally, identification and quantification of these risk factors would allow for creation of a clinically useful scoring system that could be rapidly applied preoperatively to determine which patients are most likely to benefit from preoperative embolization. Carpenter et al. [4] 1 Renal Patel et al. [14] 1 Unknown primary Bowers et al. [3] 5 Renal Roscoe et al. [17] 10 Renal Barton et al. [1] 3 Not specified Sun and Lang [21] 11 Renal Kickuth et al. [11] 14 Not specified Pazionis et al. [15] 30
